S'abonner

Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis - 05/03/25

Doi : 10.1016/S1470-2045(24)00731-9 
Ryan S Huang, MSc a, Ronald Chow, MS a, Ali Benour, BSc a, David Chen, BMSc a, Gabriel Boldt, MLIS b, Christopher J D Wallis, MD c, Anand Swaminath, MD d, Charles B Simone, ProfMD e, Michael Lock, ProfMD b, Srinivas Raman, MD f, ⁎
a Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada 
b London Regional Cancer Program, London Health Sciences Centre, Schulich School of Medicine, University of Western Ontario, London, ON, Canada 
c Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada 
d Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada 
e Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA 
f Department of Radiation Oncology, Princess Margaret Cancer Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada 

* Correspondence to: Dr Srinivas Raman, Department of Radiation Oncology, Princess Margaret Cancer Centre, Temerty Faculty of Medicine, University Health Network, University of Toronto, Toronto, ON, M5G 2M9, Canada Department of Radiation Oncology Princess Margaret Cancer Centre Temerty Faculty of Medicine University Health Network University of Toronto Toronto ON M5G 2M9 Canada

Summary

Background

Non-invasive and minimally invasive ablative treatments, including stereotactic body radiotherapy (SBRT), radiofrequency ablation, microwave ablation, and cryoablation, have emerged as key treatment options for managing renal cell carcinoma, especially for patients who are unsuitable for surgery. We aimed to compare the clinical efficacy and safety of these emerging treatment methods in patients with localised renal cell carcinoma.

Methods

In this systematic review and meta-analysis, we searched PubMed (MEDLINE), Embase, and the Cochrane Library for publications between Jan 1, 2000, and March 1, 2024. Eligible articles were observational studies and randomised controlled trials including at least five adult patients (age ≥18 years) with primary and localised renal cell carcinoma treated with SBRT, radiofrequency ablation, microwave ablation, or cryoablation and that reported on local control outcomes. Two reviewers independently screened titles and abstracts and then full texts of eligible studies were independently evaluated by the same reviewers, with disagreements resolved via discussion or consultation with a third reviewer. Summary estimates were extracted from published reports manually using a standardised data extraction form. The primary endpoint was local control rate at 1 year, 2 years, and 5 years after start of treatment. A meta-analysis was conducted using a DerSimonian and Laird model to summarise local control rates. Publication bias was evaluated using funnel plots and Egger’s test. We also recorded the frequency and severity of adverse events after treatment on the basis of the Common Terminology Criteria for Adverse Events (version 5.0) and Clavien-Dindo complication index. The study protocol was prospectively registered with PROSPERO, CRD42024511840.

Findings

We identified 6668 records, of which 330 were assessed via full-text review, and 133 were included in our systematic review and meta-analysis. The eligible studies included data for 8910 patients (mean age 67·9 years [SD 7·3], 2518 [31·4%] of 8018 patients with available data were female and 5500 [68·6%] were male). Local control rates for SBRT were 99% (95% CI 97–100; I2=6%) at 1 year, 97% (95–99; I2=0%) at 2 years, and 95% (89–98; I2=42%) at 5 years; for radiofrequency ablation were 96% (94–98; I2=73%) at 1 year, 95% (92–98; I2=77%) at 2 years, and 92% (88–96; I2=78%) at 5 years; for microwave ablation were 97% (95–99; I2=74%) at 1 year, 95% (92–98; I2=77%) at 2 years, and 86% (75–94; I2=66%) at 5 years; and for cryoablation were 95% (93–96; I2=61%) at 1 year, 94% (91–96; I2=69%) at 2 years, and 90% (87–93; I2=74%) at 5 years. The proportion of patients who reported grade 3–4 adverse events was 3% (121 of 3726) after cryoablation, 2% (39 of 2503) after radiofrequency ablation, 1% (22 of 2069) after microwave ablation, and 2% (11 of 612) after SBRT. Risk of bias was moderate in most studies (70 [53%] of 133) and no publication bias was observed.

Interpretation

All investigated ablative methods continue to represent effective treatment choices in renal cell carcinoma, and these findings support multi-disciplinary discussions of these treatment methods, along with surgery and surveillance, to individualise treatment decisions in these patients. Future research should aim to conduct randomised controlled trials across larger patient populations to further elucidate the long-term oncological and survival outcomes associated with these treatments.

Funding

None.

Le texte complet de cet article est disponible en PDF.

Plan


© 2025  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 26 - N° 3

P. 387-398 - mars 2025 Retour au numéro
Article précédent Article précédent
  • The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials
  • John Nikitas, Parsa Jamshidian, Alison C Tree, Emma Hall, David Dearnaley, Jeff M Michalski, W Robert Lee, Paul L Nguyen, Howard M Sandler, Charles N Catton, Himanshu R Lukka, Luca Incrocci, Wilma Heemsbergen, Floris J Pos, Soumyajit Roy, Shawn Malone, Eric Horwitz, Jessica Karen Wong, Stefano Arcangeli, Giuseppe Sanguineti, Tahmineh Romero, Yilun Sun, Michael L Steinberg, Luca F Valle, Joanne B Weidhaas, Daniel Spratt, Donatello Telesca, Amar U Kishan
| Article suivant Article suivant
  • Cancer surveillance in the Eastern Mediterranean region: a 10-year International Agency for Research on Cancer–WHO Regional Office for the Eastern Mediterranean collaboration
  • Ariana Znaor, Heba Fouad, Mariam Zahwe, Sultan Eser, Ibtihal Fadhil, Isabelle Soerjomataram, Asmus Hammerich, Freddie Bray

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.